You are here

Development of Small Molecule Therapeutics for Emerging Viral Agents

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911QY-20-P-0080
Agency Tracking Number: C192-006-0023
Amount: $96,111.02
Phase: Phase I
Program: SBIR
Solicitation Topic Code: CBD192-006
Solicitation Number: 19.2
Solicitation Year: 2019
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-02-06
Award End Date (Contract End Date): 2020-11-06
Small Business Information
11189 Sorrrento Valley Rd, Ste 104
San Diego, CA 92121
United States
DUNS: 962535782
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Greg Henkel
 VP of Research
 (760) 271-6574
Business Contact
 Ken McCormack
Phone: (858) 766-0495
Research Institution

Arenaviruses comprise a diverse group of Old (Africa) and New World (Americas) species. Several species are associated with hemorrhagic fever (HF) with case-fatality rates as high as 30%. Arenaviruses infection typically occurs via the mucosal route through contact with excretions of an infected rodents although direct human-to-human transmission may occur in clinical settings. Lassa arenavirus endemic to Western Africa has significantly higher rate of annual infections (over 300,000) between both Old and New World species. With the exception of a New World Junin virus vaccine, no approved broad-spectrum vaccines or therapeutics are available. We identified a novel broad-spectrum small molecule arenavirus entry inhibitor that exhibits remarkable post-exposure in vivo efficacy including, a guinea pig Lassa model. However, efficacy was evaluated when the virus was inoculated via parenteral routes. Interestingly, current vaccines and monoclonal antibodies when tested in Ebola animal models demonstrate less efficacy when virus is inoculated via aerosol route versus parenteral routes. Because of the potential for aerosol weaponization as well as natural infection via mucosal route, it is important to demonstrate efficacy against arenaviruses through the typical route of infection. Therefore, we propose to evaluate efficacy of our lead candidate in a guinea pig aerosol Lassa model.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government